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Cytokines in immunodeficient patients with invasive 
fungal infections: an emerging therapy 
Emmanuel Roilides, Cristina Gil Lamaignere,(t) and Evangelia Farmaki(l) 
Immune response is the major contributor to host defense against opportunistic fungal infections such as candidiasis, 
aspergillosis and other rare infections. A number of cytokines have been developed and studied in vitro for activity 
against fungal pathogens. The most studied among them in relation to fungal infections are granulocyte colony- 
stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony- 
stimulating factor (M-CSF) and interferon-y (IFN-y). The fields where these cytokines have been predominantly 
studied or where they may need more study are primary immunodeficiencies of the phagocytic cells, neonatal age, 
human immunodeficiency virus infection and cancer-related conditions such as neutropenia and hemopoietic cell 
transplantation. In this review, the in vitro, experimental animal and clinical data of cytokines are summarized in 
relation to invasive candidiasis, aspergillosis and emerging fungal infections. Cytokine administration to patients 
together with antifungal agents, as well as transfusion of cytokine-upgraded phagocytes, are promising immuno- 
therapeutic modalities for further research. 
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Immune response is the major contributor to host 
defense against opportunistic fungal infections. This is 
illustrated by the finding that when immune components 
are absent or dysfunctional, invasive fungal infections 
occur. Neutropenia is a particularly major risk factor for 
the development and outcome of fungal infections. 
Patients with cancer and/or hemopoietic cell trans- 
plantation usually develop neutropenia secondary to 
their malignancies or to their chemotherapy treatment. 
Other risk factors are corticosteroid treatment and 
phagocytic dysfunction occurring in immunosuppressing 
conditions, including bone marrow transplantation 
(BMT) and infection with human immunodeficiency 
virus (HIV). 
While infections due to Candida spp. and 
Aspergillus spp. are the most common, previously rarely 
encountered opportunistic fungi have emerged as 
important pathogens. As examples, Trichosporon spp., 
Fusarium spp., Scedosporium spp. and Penicillium 
marneffei can cause invasive infections. In the setting of 
neutropenia, overall mortality of candidiasis exceeds 
60%’ while aspergillosis and fusariosis can have a 
mortality of >90%. 2,3 Unfortunately, these infections are 
often only minimally responsive to antifungal therapy, 
especially in patients with neutropenia, where even the 
most efficient antifungal agents have limited efficacy. 
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Therefore, new therapeutic approaches are urgently 
needed. 
Rapid advances in understanding the pathogenesis 
of these infections, combined with the availability of 
recombinant cytokines, have opened the way for 
immunotherapeutic approaches. A schematic general 
view of the effects of cytokines on the antifungal 
function of phagocytes through transduction of activ- 
ation signals is shown in Figure 1. The critical role of 
phagocytic immunity has become evident, and numer- 
ical as well as functional reconstitution of effector cells 
by treatment with cytokines and/or white blood cell 
transfusions (WBCTx) has been attempted. Cytokines 
that are of most interest due to their ability to up- 
regulate the function of phagocytes and the fact that 
they have no major toxicity, are granulocyte colony- 
stimulating factor (G-CSF), granulocyte-macrophage 
colony-stimulating factor (GM-CSF), macrophage 
colony-stimulating factor (M-CSF) and interferon-y 
(IFN-?I). There is a large body of preclinical data as well 
as recent studies of cytokine use in the prophylactic and 
therapeutic management of fungal infections. The most 
important of these data are summarized below. 
IN VITRO EFFECTS OF CYTOKINES ON 
ANTIFUNGAL DEFENSE 
Invasive candidiasis 
Cytokines modulate the ability of phagocytes to ingest 
and kill Candida spp., thus influencing host defense 
against infection. Downregulation of Thl-profile 
responses may allow Candida to evade intracellular 
destruction by phagocytes. 4,5 As well as being critical in 
the association between fungus and host at the mucosa, 
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Thl cytokines may also be important in invasive infec- 
tions, when the recruitment of antigen-specific lympho- 
cytes and locally high cytokine concentrations are 
required to stimulate the anticandidal activities of 
nonspecific effector cells, including neutrophils (PMNs) 
and macrophages.6 The role of cytokines, such as G-CSF, 
GM-CSF, M-CSF and IFN-y, appears to be very 
important in this process. The in vitro effects of 
hemopoietic cytokines are summarized in Table 1. 
IFN-y, a potent immunomodulator of Thl pattern of 
response, enhances the phagocytic function against 
fungi7 and, in particular, the anti-Can&a activity of 
both PMNs and monocytes (MNCs), as has been shown 
in several in vitro studies.*.” Tumor necrosis factor-a 
(TNF-a), despite its toxicity, is promising because of its 
potency as an immunoenhancing cytokine. It has been 
shown to enhance the fungicidal activity of PMNs 
against C. albicans and C. glabrata blastoconidia,8J0 
whereas the results with pseudohyphae of C. albicans 
were equivocal.” Other cytokines such as interleukin-15 
(IL-1.5)” have been shown to have anti-Can&da activity, 
but their experimental animal and clinical data are very 
limited. 
Invasive aspergillosis 
Cytokines play an important role in the host response 
and pathogenesis of invasive aspergillosis. Both 
immunoenhancing and immunoregulatory cytokines 
have been shown to modulate host defenses against 
aspergillosis in vitro and in vivo.12 The most important 
in vitro effects of hemopoietic cytokines are summar- 
ized in Table 2. 
In addition, the significance of Thl and Th2 patterns 
of response to invasive aspergillosis has been recently 
demonstrated.‘“.‘4 Incubation of PMNs with IFN-y 
increased oxidative burst and PMN-mediated damage to 
both serum-opsonized and non-opsonized hyphae of 
A. fumigatus. I5 Furthermore, available in vitro data 
suggest that the effects of IFN-y on anti-Aspergillus 
activities of human PMNs and MNCs can be combined 
with the effects of either G-CSF or GM-CSF, and serve 
as a basis for potential experimental animal and clinical 
combinational use of these cytokines.ls.lh 
IFN-)I was also able to reverse corticosteroid- 
induced deficiency of certain functions of mononuclear 
phagocytes.‘7-1y While dexamethasone suppressed the 
fungicidal activity of human MNCs against A. fumigatus 
evidenced as OZ- production in response to hyphae and 
as hyphal damage, IFN-y was able to restore these 
activities.20 These effects correlated with in vivo results 
that IFN-y had favorable effect on invasive aspergillosis 
in mice immunosuppressed with corticosteroids*’ as 
mentioned below. Recently, G-CSF, GM-CSF and IFN-y 
were administered to healthy volunteers, and their ex 
vivo effects on PMNs and MNCs were compared. IFN-y 
exhibited the broadest antifungal activity and enhanced 
hyphal damage to A. fumigatus.22 
The effects of recombinant human TNF-a on 
antifungal activities of PMNs, MNCs and pulmonary 
alveolar macrophages (PAMs) against A. fumigatus 
have also been investigated. While the effects on MNC 
functions were moderate, incubation of PMNs with 
TNF-a enhanced human PMN 02~ production in res- 
ponse to PMA, FMLP and non-opsonized A. fumigatus 
hyphae, as well as PMN-induced hyphal damage. Incu- 
bation of PAMs with TNF-a increased phagocytosis of 
A. fumigatus conidia but did not affect intracellular 
killing of conidia.*” 
Table 1. Significant in vitro effects of hemopoietic cytokines on 
the anti-Candida function of phaqocytes 
G-C% 
7‘ PMN oxidative burst in response to blastoconidia and 
pseudohyphae of C. albicansE5 
? PMN fungicidal activity after long incubation with 
C. a/bicanP 
t PMN hyphal damage of C. tropicalis, C. parapsilosis and 
C. a/bicans87~88 
GM-CSF 
‘? anti-Candida activities of PMNs and MNCS*~.~~ 
M-CSF 
? MNC-mediated phagocytocisgOcgl 
‘? MNC conidial damageg0,g1 
1‘ MNC 02- production in response to FMLPgOsgl 
MNC=monocyte. 
f Recognition? 
Non oxidative stimulation 
Intracellular & extracellular killing 
Cytokine secretion 
Figure 1. Schematic model of the effect of cytokines on the function of phagocytes through transduction of activation signals. JAK, 
Janus kinase; STAT, signal transducer and activator of transcription; MAP, mitogen-activated protein kinase; NFKB, nuclear 
tranSCriptiOn factor KB. 
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Invasive infections due to rare or emerging fungi 
Trichosporon spp. and Scedosporium spp., both drug- 
resistant fungi, as well as Fusarium spp. and F! marneffei 
have emerged as important pathogens in immuno- 
compromised patients. 24-33 Risk factors for infection by 
these rare fungi are prolonged neutropenia and corti- 
costeroid therapy.25,27,38-41 The modulatory effects of 
cytokines on phagocytic activity against these fungi are 
summarized in Table 3. 
EXPERIMENTAL ANIMAL AND CLINICAL 
STUDIES OF CYTOKINE THERAPY 
Chronic granulomatous disease (CGD) 
Prevention Early studies have shown that IFN-y 
enhances the oxidative metabolism of PMNs and MNCs 
of patients with CGD in vitro and in vivo.3”36 In a large, 
prospective, randomized, placebo-controlled trial, the 
incidence of invasive fungal infections in the group of 
CGD patients who received 50 ug/m2 IFN-)I three times 
a week was reduced from 24% of controls to 4% in 2 
years.37 In this study, IFN-y administration did not affect 
oxidative burst production suggesting no causative role 
of oxidative burst enhancement on microbicidal activity 
of patients’ PMNs. The majority of cases in which 
oxidative burst was enhanced were patients with variant 
Table 2. Significant in vitro effects of hemopoietic cytokines on 
the anti-Aspergillus function of phagocytes 
G-CSF 
? PMN 02- production in response to hyphae of 
A. fumigatusq5 
7 PMN hyphal damage15 
restores the corticosteroid immunosuppression of PMN 
antifungal activities47,g2 
1‘ PMN conidial damageg3 
GM-CSF 
T‘ PMN hyphal damageg4 
t 02- production by PMNs and MNCs in response to PMA and 
hyphae16ng4 
7 MNC hyphal damageI 
restores the corticosteroid immunosuppression of MNC 
antifungal activitiesZo 
M-CSF 
1‘ MNC hyphal damageg5 
? MNC 02- production in response to PMAg5 
?‘ MNC conidial damageg5 
Table 3. In vitro effects of cytokines on the antifungal function 
of phagocytes in response to rare fungi 
l GM-CSF, M-CSF and IFN-y 1‘ anti-T asahii activity of MNCS~~ 
. G-CSF, GM-CSF and IFN-y 1‘ anti-E solani activity of 
phagocytes22 
l GM-CSF and IFN-)I ? 02m production by PMN in response to 5. 
prolificans hyphae32 
l M-CSF ‘? 02- production by PMN in response to /? marneffei 
conidia33 
X-linked forms of CGD, which is the minority form of 
the disease. In an ex vivo accompanying study of some 
of the patients from the above investigation, PMNs of 
IFN-y-treated patients resulted in more damage to 
Aspergih hyphae than PMNs of controls.38 From these 
and other studies, it appeared that enhancement of 
antifungal activity against mold hyphae is not closely 
related to modulation of oxidative burst. Probably, non- 
oxidative mechanisms are more important than oxidative 
metabolites in hyphal damage.3” 
In a subsequent double-blind randomized study, 
however, CGD patients treated with 100 ug/m2 IFN-)I 
for 2 consecutive days did exhibit a higher capacity of 
oxidative burst after stimulation with FMLP or PMA 
and increased damage to A. fumigatus hyphae as com- 
pared to patients treated with 50 yg/m2 IFN-y or before 
initiation of IFN-y administration.4” These findings 
may be relevant to the decreased incidence of invasive 
aspergillosis observed in CGD patients treated with 
IFN-)I prophylactically. 
Therapy Many cases have been reported in the 
literature of patients with invasive fungal infections, the 
vast majority of which have been due to Aspergillus spp., 
who were cured with combined antifungal therapy and 
IFN-y. Those patients were not receiving IFN-)I prophy- 
lactically. Use of other cytokines or other immuno- 
therapies has been rare in CGD patients. One patient 
with X-linked CGD and invasive multifocal infection 
due to A. nidulans was successfully treated by HLA- 
genoidentical BMT, G-CSF-elicited PMNs, G-CSF and 
liposomal amphotericin B. The infection had been 
unresponsive to treatment with amphotericin B and 
IFN-)I. At 2 years post-BMT, the patient was well, with 
full immune reconstitution and no sign of Aspergillus 
infection.41 
Another interesting case was that of a 15-year-old 
male with X-linked CGD who developed a lobar pneu- 
monia and tibia1 osteomyelitis due to the filamentous 
fungus Chrysosporium zonatum, while prophylaxis with 
IFN-y was just initiated. The mold was isolated from 
sputum and affected bone, and hyphae were observed 
in the bone by histopathology. Therapy with liposomal 
amphotericin B and IFN-y eradicated infection from 
both sites.42 
Neonates 
Little is known about the antifungal activity of neonatal 
phagocytes and its modulation by cytokines. IFN-)I 
production is defective in neonates,43 and IFN-), treat- 
ment enhances the antifungal activity of neonatal 
macrophages against C. albicans.44 Despite enhancing 
the antifungal activity of adult monocytes and macro- 
phages, M-CSF did not significantly affect the activity of 
neonatal MNCs against C. aZbicans.45 As more fungal 
infections are seen in the neonatal intensive care unit 
now and more high-risk very-low-birthweight newborns 
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survive, the roles of cytokines in the prevention and 
treatment of invasive fungal infections in the nursery 
remain to be defined. 
HIV infection 
Aspergillosis has become an important opportunistic 
infection in HIV-infected patients.46 PMNs and MNC- 
derived macrophages from HIV-infected patients 
possess decreased ability to damage hyphae and to 
ingest conidia of A. jcumigatus, respectively.47.48 These 
defects may be related to the well-described CD4+T- 
helper lymphocyte dysfunction of these patients.4” 
Interestingly, the PMN defect is partially correctable by 
G-CSF in vitro.47 In addition, in a randomized, multi- 
center, controlled trial of patients with advanced HIV 
infection, G-CSF decreased the incidence and duration 
of severe neutropenia, the incidence of bacterial infec- 
tions, hospital days, and duration of intravenous anti- 
biotics.50 No mention, however, of any fungal infections 
was included in the study. A more recent phase III study 
of recombinant IFN-y administration showed a trend of 
decreased incidence of oral/esophageal candidiasis 
compared to control subjects.“’ 
Cancer-related therapy 
Malignancies and the related immunodeficiencies 
constitute the broadest field of cytokine use. Thus, most 
of the preclinical and clinical studies have focused on 
this patient population.The cytokines under review have 
been studied preclinically, although clinical studies are 
still missing for most of them. 
Experimental animal studies In one of the earliest 
studies of the use of cytokines in animal models of 
fungal infections, G-CSF given to cyclophosphamide- 
treated mice was reported to offer protection from sub- 
sequent development of aspergillosis. In that study, 
steroid-treated mice were protected only when simul- 
taneous antifungal chemotherapy was administered.52 
In a more recent study, mice immunosuppressed with 
either hydrocortisone or 5-fluorouracil were infected 
intranasally with A. fumigatus. Beginning 3 days before 
infection, some groups of mice were given recombinant 
G-CSF, the antifungal triazole SCH.56592 (currently 
named posaconazole), or both. In corticosteroid- 
pretreated mice, G-CSF strongly antagonized the 
antifungal activity of SCH56592. While the drug reduced 
fungal burden in lung tissue and prolonged survival, the 
combination therapy reversed this effect. In contrast, 
mice made neutropenic with 5-fluorouracil and then 
infected with A. fumigatus benefited from either G-CSF 
or triazole, and the effect of the combination was 
additive. These findings suggest that host factors contri- 
bute in different ways to the outcome of cytokine 
therapy in aspergillosis.s” 
The effect of G-CSF was also investigated on acute 
disseminated C. albicans infection in non-neutropenic 
mice. Mice treated with a single dose of G-CSF showed 
a significantly reduced mortality and fungal growth from 
kidneys, spleen and liver.54 
On the other hand, in a neutropenic murine model 
of disseminated trichosporonosis, G-CSF (30-100 pg/kg 
per day) administered either before or after infection 
improved the survival rate from less than 25% up to 
100% and led to organ clearance. However, GM-CSF 
(0.8-2 pg/kg per day) decreased the survival rate. GM- 
CSF increased PMN counts less significantly than did G- 
CSF and increased the lethality, with a high level of 
TNF-a in bronchoalveolar lavage fluid. These results 
suggested that other host defense mechanisms, such as 
TNF-a overproduction in the lungs, have an important 
role in the prognosis of trichosporonosis.‘” 
In acute murine candidiasis, Cenci et al found that 
M-CSF administration protected mice from a sub- 
sequent lethal challenge with C. albicans. In this model, 
increased survival and reduced recovery of fungi from 
the organs was observed.56 
Furthermore, the effects of M-CSF (100-600 pg/kg 
per day) in augmenting pulmonary host defense against 
A. fumigatus were studied in neutropenic rabbits with 
pulmonary aspergillosis, starting 3 days pre-inoculation 
and then throughout neutropenia. Rabbits receiving 
prophylactic M-CSF had significantly increased survival 
and decreased pulmonary injury, as evidenced by com- 
puterized tomographic scanning and histopathology. 
Microscopic studies demonstrated greater numbers and 
more activated PAMs in lung tissue of rabbits receiving 
M-CSF in comparison to controls. PAMs harvested from 
M-CSF-treated rabbits exhibited significantly greater 
phagocytosis of A. fumigatus conidia as compared to 
PAMs from control rabbits.s7 
The effect of recombinant rat IFN-y on acute 
disseminated C. albicans infection was investigated in 
mice. One intravenous dose of IFN-y shortly before or 
simultaneously with the inoculation of non-immuno- 
suppressed mice decreased the growth of C. albicans 
from kidneys, spleen and liver. However, it did not 
reduce the fungal growth of C. albicans in cyclo- 
phosphamide-pretreated mice. These findings suggest 
that IFN-y enhances host resistance against acute 
disseminated C. albicans infection in mice through 
activation of PMNs.‘~ 
In corticosteroid-treated mice with invasive 
aspergillosis, TNF-a succeeded in decreasing mortality 
(from 40-60% to 0%) and recovery of fungi from organs 
as demonstrated by culture and histology.*’ In another 
study, intratracheal challenge of both neutropenic and 
non-neutropenic mice with A. fumigatus conidia 
resulted in an increase in lung TNF-a levels, which 
correlated with the histologic development of a peri- 
bronchial infiltration of PMNs and MNCs. Neutraliz- 
ation of TNF-a resulted in an increase in mortality in 
both normal and cyclophosphamide-treated animals, 
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which was associated with increased lung fungal burden. 
Depletion of TNF-a resulted in a reduced lung PMN 
influx in both normal and cyclophosphamide-treated 
animals, which occurred in association with a decrease 
in lung levels of the chemokines macrophage i&am- 
matory protein-2 and macrophage inflammatory 
protein-la. In cyclophosphamide-treated animals, 
intratracheal administration of a TNF-a agonist peptide 
3 days before the administration of Aspergillus conidia 
resulted in improved survival. This study indicated that 
TNF-o is a critical component of innate immunity in 
both immunocompromised and immunocompetent 
hosts, and that pretreatment with a TNF-a agonist 
peptide in a compartmentalized fashion can significantly 
enhance resistance to A. fumigatus in neutropenic 
animals.59 
Clinical studies In cancer patients, cytokines, mostly 
G-CSF and GM-CSF, have been used to shorten the 
duration of therapy-induced leukopenia and as adjunc- 
tive therapy in patients with febrile neutropenia. How- 
ever, their role in the prevention of fungal infections has 
not been established, as very few of these studies have 
attempted to address this issue. 
A randomized trial of G-CSF was carried out to 
investigate the efficacy and toxicity of G-CSF in 119 
severely neutropenic patients with hematologic malig- 
nancies after intensive chemotherapy and infection. 
Patients were assigned randomly to receive either anti- 
biotics alone (ceftazidime plus amikacin) or the same 
antimicrobial regimen plus G-CSF (5 pg/kg per day). 
Patients who received antibiotics plus G-CSF had more 
clinical responses (82% versus 60%) less super- 
infections as well as improved mortality, fewer days in 
hospital, and reduced antibiotic use. Fungal infections 
occurred only in the group treated with antibiotics 
alone. Toxicity secondary to G-CSF was absent.60 
A prospective, randomized, placebo-controlled 
phase III study of GM-CSF in acute myelogenous 
leukemia was conducted in 124 patients 55-70 years of 
age by the Eastern Cooperative Oncology Group. GM- 
CSF or placebo were administered from day 11 post- 
induction. A higher rate of complete response was 
observed among the patients treated with GM-CSF and 
longer overall survival. In addition, lower infection- 
related toxicity was observed. Among patients with 
pneumonia, mortality was as follows: 2/14 patients 
(14%) in the GM-CSF group, and 7/13 (54%) in the 
placebo group (P=O.O46). Fungal infection-related 
mortality in the GM-CSF group was l/52 (2%) as 
compared to the placebo group, in which was 9/47 (19%) 
P=0.006).6’,6’ 
The mortality of the patients who received GM-CSF 
or placebo in this study according to the etiologic agent 
was mentioned in a more recent publication.63 There 
were 11 patients with aspergillosis, 7 with candidiasis 
and 2 with infections due to other fungi. Only 1 of 8 
patients who had been randomized to receive GM-CSF 
and developed fungal infection died (13%). This con- 
trasted with 9 of 12 patients on placebo (75%, P=O.O2). 
No apparent difference between aspergillosis and 
candidiasis was noted with these very small numbers of 
patients. 
A non-randomized study of M-CSF administration 
to neutropenic cancer patients was reported, Among 
them, 30 patients suffered from invasive candidiasis, 15 
from invasive aspergillosis, and 1 from mucormycosis. 
Overall, there was a trend of decreased incidence of 
fungal infections. There was, however, significantly 
greater survival in patients with candidiasis and 
Karnofsky score >20% compared with historical 
controls (P~0.05).~~ 
A double-blind controlled study of M-CSF was 
conducted in patients with acute myeloid leukemia and 
febrile neutropenia. Although decreased incidence and 
duration of febrile neutropenia and significant decrease 
of use of systemic antifungals was found, no impact on 
disease-free survival or on incidence of specific infec- 
tions was observed.6s 
CYTOKINES IN PROVEN FUNGAL INFECTIONS 
Cytokine administration to patients 
Several case reports have suggested the value of 
hemopoietic cytokines in treating invasive fungal 
infections. Some of them are mentioned briefly in this 
review. G-CSF has been administered together with 
amphotericin B in a patient with acute myelogenous 
leukemia and allogeneic BMT suffering from dissemin- 
ated infection due to T. asahii with a successful outcome. 
Two other patients with acute leukemia and progressive 
chronic disseminated candidiasis were treated with a 
combination of IFN-y and GM-CSF in addition to 
antifungal therapy and they were cured.67 
A pilot study of eight neutropenic patients with 
invasive fungal infections was conducted with GM-CSF 
as adjuvant treatment. There were six responses, with 
four complete responses among two patients with 
Aspergillus infection (one responded), five Candida spp. 
cases (four responded) and one Trichosporon case 
(responded).68 The dose of GM-CSF used in this study 
was excessive ranging up to 700 ug/m2, and was followed 
by increased toxicity. 
A subsequent open study of GM-CSF in proven 
invasive fungal infections in neutropenic cancer patients 
conducted in 17 patients did not show similar favorable 
results. Eight of the patients suffered from candidemia, 
eight from pulmonary aspergillosis, and one from 
fusariosis. They were treated with GM-CSF 5 ugikg and 
amphotericin B 1 yg/kg. There were six deaths, and the 
authors felt that the regimen failed to improve outcome.69 
A retrospective analysis of 123 cases of invasive 
aspergillosis from 20 hospitals in eight countries was 
conducted by European Organization for Research and 
Treatment of Cancer Invasive Fungal Infection Cooper- 
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ative Group in hematologic patients. Although not an 
objective of the study, 33% of the patients had taken a 
growth factor (mostly G-CSF) in addition to antifungal 
agent(s). No significant influence on outcome of the 
growth factor was observed.‘” 
Finally, a multicenter study of administration of 
G-CSF in non-neutropenic patients with invasive 
candidiasis has been conducted and recently completed 
in Europe. The patients who had higher numbers of 
PMNs due to G-CSF had more favorable outcome than 
the patients who did not increase their PMN counts. The 
results of this study have been presented in meetings but 
not published yet. 
Immunoreconstitution through cytokine-elicited white 
blood cell transfusions 
Based on encouraging results of several experimental 
animal studies that demonstrated the efficacy of 
WBCTx therapy for the eradication of infection, a series 
of clinical trials were conducted in patients with 
neutropenia-related infections. Most of the studies 
showed that WBCTx could be life-saving among those 
patients with prolonged neutropenia7’-74 or could 
improve overall survival. 7s However, methodological 
problems as well as issues related to the relatively high 
cost of the procedure, significant adverse effects to the 
recipient (fever, chills, hypotension, pulmonary infil- 
trates, respiratory distress, transmission of cytomegalo- 
virus, graft-versus-host disease, alloimmunization and 
hemolytic reactions), insufficient quantities of PMNs 
used for transfusion76 and the development of newer 
and more effective antibiotics, made WBCTx less 
attractive. 
A new need for WBCTx therapy became apparent 
due to the increased incidence of neutropenia-related 
fungal infections and the limited efficacy of antifungal 
agents in this setting. Recombinant G-CSF has been 
shown to stimulate the proliferation and differentiation 
of PMNs in vitro and to increase the PMN count safely 
in patients with neutropenia.” These results raised the 
possibility that administration of G-CSF to white blood 
cell (WBC) donors would increase their PMN counts to 
levels that would lead to a higher yield of better-quality 
PMNs. 
Thus, in one study, 10 profoundly neutropenic 
patients (<lOO/uL) having refractory fungal infections 
were treated with daily WBCTx obtained from donors 
treated daily with 5 yg/kg of G-CSF subcutaneously.‘* 
Half of the recipients showed a favorable outcome of 
the infection after WBCTx. Donors achieved a 4-IO-fold 
increase of their PMN count and the mean PMN yield 
was 3.7~10”‘. Recipients achieved median l- and 24-h 
post-transfusion PMN counts of 780 and 426/uL, respec- 
tively. In another study, G-CSF-primed PMN trans- 
fusions were administered to two neutropenic patients 
with C. tropicalis fungemia in combination with ampho- 
tericin B. resulting in elimination of the infection.79 
More recently, G-CSF-elicited WBCTx were used to 
treat 15 adult neutropenic patients (<5OO/yL) with 
documented and refractory fungal infections in a pilot 
studyxo All 15 adult patients had hematologic malig- 
nancies and 7 had been treated with BMT. The cases 
included 11 mold infections (7 aspergillosis, 3 fusariosis, 
1 unidentified) and 4 yeast infections (3 candidiasis, 1 
trichosporonosis). Eight of the patients had evidence for 
widely disseminated infection. At the time of institution 
of WBCTx, all of the infections had been progressive 
despite appropriate antifungal treatment for a median 
of 10 days, and the patients had been neutropenic for a 
median of 23 days. At the end of WBCTx therapy, 11 of 
15 patients had a favorable response (9 improved and 2 
stabilized), and in 7 of them the favorable response 
appeared to be substantially due to WBCTx. Those 
patients in whom WBCTx therapy was started early 
during neutropenia and shortly after diagnosis of fungal 
infection were more likely to respond. The favorable 
responses were still seen 3 weeks after the end of 
WBCTx therapy in 8 of 11 responders. Owing to special 
efforts to select only blood-related donors and non- 
alloimmunized recipients, the frequency of adverse 
reactions was ~5%. Donors tolerated the treatment well 
and achieved a median PMN count of 29.4xlO’/uL that 
led to a mean PMN yield of 4.1x101”, and mean l-h 
and 24-h post-transfusion PMN counts of 594 and 
396/uL. respectively. Although this was a small pilot 
study, it demonstrated that G-CSF-enhanced WBCTx 
therapy can be life-saving for patients with refractory 
neutropenia-related fungal infections. More information 
about the long-term safety of donors’ treatment with 
G-CSF is needed before firm recommendations on the 
use of G-CSF-elicited WBCTx are made.81 
PHARMACOLOGY, TOXICOLOGY AND 
ECONOMICS 
Two forms of G-CSF are commercially available. One is 
a recombinant non-glycosylated protein expressed in 
Escherichia coli (filgrastim). The other is a glycosylated 
form expressed in Chinese hamster ovarian cells in vitro 
(lenograstim). Both products have the same net effect, 
acceleration of myelopoiesis and enhancement of 
functional responses. As an immediate effect, G-CSF 
causes an actual decrease in PMN count, which is 
followed by a sustained dose-dependent rise in PMN 
counts. 
GM-CSF is a recombinant non-glycosylated protein 
expressed in E. coli (molgramostim) and glycosylated 
protein expressed in Saccharomyces cerevisiae (sargra- 
mostim) or in mammalian cells (regramostim). GM-CSF 
transiently decreases leukocyte counts immediately 
after administration and causes sustained rises in PMN, 
eosinophil and MNC counts afterwards. 
GM-CSF has been described in some cases as 
inducing pleuritic pain, pulmonary edema, and a capillary 
leak syndrome. Although bone pain is described in 20% 
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of patients receiving G-CSF, the other adverse effects 
associated with GM-CSF are not commonly observed in 
G-CSF-treated patients. The toxicity of GM-CSF 
appears to be related to the non-glycosylated prepara- 
tions expressed in E. coli. By comparison, the glyco- 
sylated form of GM-CSF is not associated with these 
adverse effects. 
The toxicity profile of recombinant GM-CSF is 
consistent with priming of macrophages for increased 
formation and release of inflammatory cytokines, where- 
as G-CSF induces production of anti-inflammatory 
factors, such as IL-1 receptor antagonist and soluble 
TNF receptors, and is protective against endotoxin- and 
sepsis- induced organ injury. Owing to its increased 
toxicity, TNF-a has not been studied in clinical trials, 
despite its highly promising immunomodulatory nature. 
Although administration of G-CSF to patients with 
acute myeloid leukemia (AML) carries the theoretical 
risk of accelerating the leukemic blast cells, this has not 
been observed. Indeed, G-CSF has been used safely in 
patients with AML and myelodysplasia.82 The adverse 
effect of GM-CSF accelerating HIV replication in MNCs 
may be offset by simultaneous administration of anti- 
retroviral agents. 
The most common adverse experiences occurring 
with parenteral IFN-y therapy are ‘flu-like’ or consti- 
tutional symptoms such as fever, headache, chills, 
myalgia or fatigue, which may decrease in severity as 
treatment continues. 
Clinical studies of cytokine use in prevention or 
adjunctive therapy in combination with antifungal 
agents are limited and do not allow specific recommen- 
dations for their cost-effective use. The issue of cost- 
effectiveness of G-CSF with regard to invasive fungal 
infections was addressed in a recently published study. 
Neutropenic patients with presumed invasive fungal 
infection were randomized to receive amphotericin B 
either alone or in combination with G-CSF (3-5 pg/kg 
daily). There were 62% responders to combination 
versus 33% to amphotericin B alone (P=O.O27). Of note, 
all non-responders received liposomal amphotericin B. 
Based on drug acquisition, hospital stay and treatment 
duration, the combination regimen was more cost 
effective.83 There is an urgent need for well-structured, 
randomized clinical trials to determine optimal dose, 
duration and timing for different combinations of 
immunotherapy and antifungal agents in high risk 
patients. 
FUTURE DIRECTIONS 
The increasing incidence of invasive fungal infections 
and the emergence of previously rare opportunistic 
fungal pathogens is of major importance in the manage- 
ment of immunocompromised patients. Host defense 
normalization and antifungal therapy form the corner- 
stone of successful treatment. The advances in under- 
standing the pathogenesis of fungal infections and cyto- 
kine involvement combined with the availability of a 
number of cytokines during the last decade have opened 
new avenues of potential applications. In tandem with 
destroying fungi using potent antifungal agents, recon- 
stitution and upregulation of immune response by either 
exogenous administration of cytokines or transfusion of 
cytokine-elicited allogeneic phagocytes appear to be 
promising adjuncts to antifungal chemotherapy for 
these difficult-to-treat and often fatal diseases. Further 
evaluation of the safety and efficacy of these immuno- 
therapeutic modalities is an urgent priority for research 
during the start of the new decade. It might be that one 
has to distinguish between patients with no PMNs or 
with dysfunctional PMNs when deciding which kind of 
cytokines to use. 84 Well-controlled studies in patients at 
very high risk of developing fungal infections, such as 
profoundly neutropenic or BMT patients should be the 
scope of future studies. 
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